IMPA1 Antibody / Inositol monophosphatase 1, 100 ug

IMPA1 antibody recognizes Inositol monophosphatase 1, a magnesium-dependent enzyme that catalyzes the dephosphorylation of inositol monophosphate to free inositol, a crucial step in the phosphatidylinositol signaling pathway. The IMPA1 gene encodes a cytosolic enzyme essential for recycling inositol phosphates derived from the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2). This reaction is critical for maintaining inositol supply for the synthesis of phosphoinositides, which regulate intracellular signaling, neurotransmission, and osmoregulation.

IMPA1 is expressed abundantly in brain, kidney, and liver, reflecting its central role in inositol metabolism. In neurons, IMPA1 supports the phosphoinositide cycle, enabling sustained neurotransmitter signaling via inositol trisphosphate and diacylglycerol pathways. Pharmacologically, IMPA1 is a well-known molecular target of lithium, a mood-stabilizing drug used in the treatment of bipolar disorder. Lithium inhibits IMPA1 activity, leading to inositol depletion and modulation of neuronal signaling, supporting the �inositol depletion hypothesis� for mood stabilization.

The human IMPA1 gene is located on chromosome 8q21.13 and encodes a 277-amino acid protein that functions as a homodimer. The enzyme binds magnesium ions within its active site to hydrolyze phosphate from a range of inositol monophosphate substrates. Structural studies have revealed conserved residues critical for catalysis and lithium binding. Genetic or functional alterations in IMPA1 have been associated with neurological disorders, cognitive deficits, and certain metabolic diseases. Experimental evidence also implicates IMPA1 in maintaining cellular osmotic balance, particularly in renal epithelial cells where inositol acts as a compatible osmolyte.

Immunohistochemical analysis using IMPA1 antibody shows strong cytoplasmic staining in neurons, glial cells, renal tubules, and hepatocytes. The antibody is useful for studying inositol phosphate metabolism, lithium pharmacology, and neuronal signaling pathways. IMPA1 antibody from NSJ Bioreagents supports research into inositol-dependent biochemical networks and the molecular mechanisms underlying psychiatric and neurological disease.